Drug
YH001
YH001 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
NCT05176509
unknownphase_1
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
NCT05448820
completedphase_1
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
NCT04357756
completedphase_1
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
NCT04699929
Clinical Trials (4)
Showing 4 of 4 trials
NCT05176509Phase 1
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
NCT05448820Phase 1
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
NCT04357756Phase 1
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
NCT04699929Phase 1
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4